[go: up one dir, main page]

MX2018014080A - Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia. - Google Patents

Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.

Info

Publication number
MX2018014080A
MX2018014080A MX2018014080A MX2018014080A MX2018014080A MX 2018014080 A MX2018014080 A MX 2018014080A MX 2018014080 A MX2018014080 A MX 2018014080A MX 2018014080 A MX2018014080 A MX 2018014080A MX 2018014080 A MX2018014080 A MX 2018014080A
Authority
MX
Mexico
Prior art keywords
fibromialgia
syndrome associated
carbamate compound
treat
prevent
Prior art date
Application number
MX2018014080A
Other languages
English (en)
Other versions
MX394245B (es
Inventor
Ju Yi Han
Jae JO Min
Gwan Hwang Sun
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of MX2018014080A publication Critical patent/MX2018014080A/es
Publication of MX394245B publication Critical patent/MX394245B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se relaciona a una composición farmacéutica para prevenir o tratar fibromialgia o un síndrome funcional asociado con fibromialgia, la composición farmacéutica que comprende: un compuesto de carbamato de la fórmula química 1 o una sal, un solvato o un hidrato farmacéuticamente aceptable del mismo; y un portador farmacéuticamente aceptable. La composición farmacéutica, de acuerdo con la presente invención, puede permitir el tratamiento eficiente de fibromialgia o un síndrome funcional asociado con fibromialgia.
MX2018014080A 2016-05-19 2017-05-18 Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia. MX394245B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160061392 2016-05-19
PCT/KR2017/005173 WO2017200318A1 (ko) 2016-05-19 2017-05-18 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Publications (2)

Publication Number Publication Date
MX2018014080A true MX2018014080A (es) 2019-04-04
MX394245B MX394245B (es) 2025-03-19

Family

ID=60325216

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014080A MX394245B (es) 2016-05-19 2017-05-18 Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.

Country Status (14)

Country Link
US (1) US10849882B2 (es)
EP (1) EP3459543B1 (es)
JP (1) JP7071287B2 (es)
KR (1) KR102489052B1 (es)
CN (1) CN109475529B (es)
AU (1) AU2017265839B2 (es)
BR (1) BR112018073553A2 (es)
CA (1) CA3024286A1 (es)
DK (1) DK3459543T3 (es)
ES (1) ES2935596T3 (es)
MX (1) MX394245B (es)
PL (1) PL3459543T3 (es)
RU (1) RU2753525C2 (es)
WO (1) WO2017200318A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102635941B1 (ko) * 2016-12-14 2024-02-13 에스케이바이오팜 주식회사 진전 또는 진전 증후군의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
WO2019098628A1 (ko) 2017-11-14 2019-05-23 에스케이바이오팜 주식회사 결신 발작 또는 결신 발작을 나타내는 뇌전증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
ES3027977T3 (en) * 2017-11-14 2025-06-17 Sk Biopharmaceuticals Co Ltd Use of a carbamate compound to prevent, alleviate or treat visceralgia or pain arising from visceral disease
WO2019098626A1 (ko) * 2017-11-14 2019-05-23 에스케이바이오팜 주식회사 후기 나트륨 전류의 증가와 관련된 질환을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
WO2020080866A1 (ko) * 2018-10-19 2020-04-23 에스케이바이오팜 주식회사 카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도
EP4062906A4 (en) * 2019-11-22 2024-01-03 SK Biopharmaceuticals Co., Ltd. ORAL PHARMACEUTICAL COMPOSITION COMPRISING A CARBAMAT COMPOUND AND PROCESS FOR PRODUCTION THEREOF
IT202300007314A1 (it) 2023-04-14 2024-10-14 Soal Pharma Srl Integratore alimentare per il trattamento della fibromialgia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) * 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
MXPA04000555A (es) * 2001-07-16 2005-06-20 Johnson & Johnson Compuestos de carbamato para utilizarse en la prevencion o tratamiento del dolor neuropatico y el dolor asociado con la cefalea acuminada y migranosa.
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
CN102803233B (zh) * 2009-06-22 2017-03-01 爱思开生物制药株式会社 制备氨基甲酸(r)‑1‑芳基‑2‑四唑基‑乙酯的方法
US8404461B2 (en) * 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
CA2779442A1 (en) * 2009-11-06 2011-05-12 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome

Also Published As

Publication number Publication date
AU2017265839B2 (en) 2022-10-27
CA3024286A1 (en) 2017-11-23
EP3459543A1 (en) 2019-03-27
DK3459543T3 (da) 2023-02-13
JP7071287B2 (ja) 2022-05-18
BR112018073553A2 (pt) 2019-03-19
ES2935596T3 (es) 2023-03-08
CN109475529B (zh) 2022-02-22
JP2019516707A (ja) 2019-06-20
RU2018144785A (ru) 2020-06-19
AU2017265839A1 (en) 2018-12-13
WO2017200318A1 (ko) 2017-11-23
EP3459543A4 (en) 2020-01-15
EP3459543B1 (en) 2022-12-21
US20190298694A1 (en) 2019-10-03
RU2753525C2 (ru) 2021-08-17
KR20170131242A (ko) 2017-11-29
CN109475529A (zh) 2019-03-15
RU2018144785A3 (es) 2020-08-11
US10849882B2 (en) 2020-12-01
PL3459543T3 (pl) 2023-04-11
MX394245B (es) 2025-03-19
KR102489052B1 (ko) 2023-01-16

Similar Documents

Publication Publication Date Title
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
DOP2019000201A (es) Compuestos inhibidores del vih
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
BR112018070602A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
MX2017009449A (es) Inhibidor jak.
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CO2020007162A2 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
TW201613887A (en) Antiproliferative compounds and methods of use thereof
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CO2021005532A2 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
MX2020003593A (es) Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos.
AR103680A1 (es) Inhibidores selectivos de bace1
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CO2019009000A2 (es) Combinaciones farmacéuticas para tratar cáncer
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
DOP2018000134A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
MX2019004842A (es) Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc.
MX2018014081A (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.
MX392555B (es) Composiciones y métodos para el tratamiento de resistencia a la insulina.
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
CL2019002025A1 (es) Derivados de pirrolotriazina como inhibidor de cinasas.